Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocyte progenitor cells; strongest in retinal amacrine cells | 0.75 |
| chemistry Open Targets | compounds already reach it: amifampridine phosphate, amifampridine, nerispirdine +3 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly dopamine synapse | 1.00 |
Knock down and overexpress KCNH5 in oligodendrocytes; measure evoked dopamine release and dopamine transporter uptake and α-synuclein uptake and myelin basic protein output under oxidative stress.
- Cell type
- oligodendrocytes
- Direction
- Both arms: public data does not say which way helps; existing compounds already reach the inhibition arm.
- Molecular readout
- evoked dopamine release and dopamine transporter uptake
- Functional readout
- α-synuclein uptake and myelin basic protein output under oxidative stress
- Rule-out
- If neither arm moves evoked dopamine release by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of KCNH5 in iPSC-derived oligodendrocytes; n = 3 differentiations; readouts: evoked dopamine release and dopamine transporter uptake; α-synuclein uptake and myelin basic protein output under oxidative stress. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- KCNH5 in oligodendrocytes, braak-0.14 (p 0.714) → +0.03 (p 0.929)receipt 4756
- KCNH5 in dopamine neurons, braak+0.35 (p 0.360) → +0.82 (p 0.006)receipt 4757
Swarm cases
receipt 4757: KCNH5 in dopamine neurons, braak
- power
- full sample +0.61 (p 0.0069, n 18), 95% CI +0.20 to +0.84. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.64 (p 0.0045, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.64 (p 0.0045, n 18). not the mix.
- skeptic
- leave-one-out range +0.55 to +0.71, sign flips 0; without severely affected donors +0.61 (p 0.0069, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for KCNH5 in dopamine neurons.
case closed: nothing better to follow up.
receipt 4756: KCNH5 in oligodendrocytes, braak
- power
- full sample -0.00 (p 0.990, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.03 (p 0.901, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.03 (p 0.894, n 18). could be the mix.
- skeptic
- leave-one-out range -0.12 to +0.14, sign flips 10; without severely affected donors -0.00 (p 0.990, n 18). fragile.
- cell type
- strongest in dopamine neurons: +0.61 (p 0.0069, n 18) vs -0.00 in oligodendrocytes. proposing dopamine neurons.
- axis
- no measure beats "tracks Braak Lewy-body stage" for KCNH5 in oligodendrocytes.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up KCNH5 · dopamine neurons · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.35 p 0.214 (needs p < 4.1e-4)
Receipts
loading the receipts